Enlivex Ltd. ENLV
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS25.48
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $9.2M | $10.6M | $19.0M | $18.7M | $12.9M | $6.1M | $5.6M | $4.0M | $1.7M | $8.9M |
| SG&A | $5.8M | $4.9M | $6.1M | $7.1M | $6.4M | $3.7M | $3.0M | $1.3M | $480.0K | $5.9M |
| Total operating expenses | $15.0M | $15.9M | $29.4M | $25.8M | $19.3M | $9.8M | $8.6M | $5.3M | $2.2M | $15.9M |
| Operating income | -$15.0M | -$15.9M | -$29.4M | -$25.8M | -$19.3M | -$9.8M | -$8.6M | -$5.3M | -$2.2M | -$15.9M |
| Pre-tax income | $1.62B | -$15.0M | -$29.1M | — | $14.5M | $11.8M | $9.4M | $4.2M | $2.5M | -$15.8M |
| Income tax | $382.6M | — | — | — | — | — | — | $4.0K | $28.0K | $216.0K |
| Net income | $1.24B | -$15.0M | -$29.1M | -$31.1M | -$14.5M | -$11.8M | -$9.4M | -$4.2M | -$2.5M | -$16.0M |
| EPS, basic | 27.04 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | — | — | — | — |
| EPS, diluted | 25.48 | -0.73 | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 | -1.40 | -0.94 | -40.13 |
| Shares, diluted (wtd. avg.) | 48.5M | 20.5M | 18.6M | 18.4M | 17.9M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.9M | $3.3M | $1.2M | $50.4M | $11.6M | $7.0M | $5.5M | $9.8M | $9.0M | $3.0M |
| Short-term investments | — | $198.0K | $5.1M | — | $62.9M | — | — | — | — | — |
| Receivables | — | — | — | — | — | — | — | $16.0K | $28.0K | $52.0K |
| Total current assets | $1.74B | $26.0M | $33.8M | $52.3M | $86.4M | $38.1M | $16.4M | $10.3M | $3.6M | $10.5M |
| Property, plant and equipment | $361.0K | $625.0K | $1.5M | $9.9M | $2.5M | $1.5M | $648.0K | $685.0K | $388.0K | $71.0K |
| Total assets | $2.33B | $27.7M | $36.8M | $67.6M | $95.1M | $40.4M | $17.6M | $11.0M | $3.6M | $10.6M |
| Total current liabilities | $9.0M | $3.8M | $6.1M | $6.6M | $4.7M | $4.4M | $6.0M | $1.1M | $460.0K | $1.9M |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M | $4.9M | $6.3M | $1.3M | $1.0M | — |
| Retained earnings | $1.11B | -$127.1M | -$112.1M | -$83.0M | -$52.0M | -$37.5M | -$25.7M | -$16.3M | -$45.8M | -$39.8M |
| Total equity | $1.93B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $11.3M | $9.7M | $8.5M | $2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.4M | -$13.0M | -$23.5M | -$24.0M | -$17.5M | -$11.0M | -$7.0M | -$3.2M | -$2.3M | -$15.5M |
| Depreciation and amortisation | $332.0K | $545.0K | $835.0K | $777.0K | $546.0K | $286.0K | $206.0K | $121.0K | $83.0K | $38.0K |
| Stock-based compensation | $1.8M | $2.1M | $2.0M | $2.7M | $2.9M | $670.0K | $810.0K | $1.0M | $121.0K | $700.0K |
| Capital expenditure | $68.0K | $103.0K | $236.0K | $8.1M | $1.6M | $1.0M | $193.0K | $461.0K | $130.0K | $18.0K |
| Investing cash flow | -$1.3M | $9.1M | -$26.0M | $62.5M | -$38.4M | -$21.0M | -$6.4M | -$501.0K | -$130.0K | $9.0M |
| Financing cash flow | $10.4M | $6.5M | $360.0K | $150.0K | $61.0M | $33.1M | $8.3M | $5.2M | $8.1M | $6.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-033857.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Receivables
- Total current liabilities
- R&D
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Receivables | $52.0K | $28.0K | $16.0K | — | — | — | — | — | — | — |
| Total current liabilities | $1.9M | $460.0K | $1.1M | $6.0M | $4.4M | $4.7M | $6.6M | $6.1M | $3.8M | $9.0M |
| R&D | $8.9M | $1.7M | $4.0M | $5.6M | $6.1M | $12.9M | $18.7M | $19.0M | $10.6M | $9.2M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |